1. Home
  2. BWEN vs ENGN Comparison

BWEN vs ENGN Comparison

Compare BWEN & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadwind Inc.

BWEN

Broadwind Inc.

HOLD

Current Price

$3.91

Market Cap

105.8M

Sector

Industrials

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.77

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWEN
ENGN
Founded
N/A
1999
Country
United States
Canada
Employees
N/A
82
Industry
Industrial Machinery/Components
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
105.8M
117.2M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
BWEN
ENGN
Price
$3.91
$1.77
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$6.00
$21.08
AVG Volume (30 Days)
472.0K
929.4K
Earning Date
05-14-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
360.00
N/A
EPS
N/A
N/A
Revenue
$146,785,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.88
$1.40
52 Week High
$5.52
$12.25

Technical Indicators

Market Signals
Indicator
BWEN
ENGN
Relative Strength Index (RSI) 36.13 42.27
Support Level $1.97 $1.68
Resistance Level $5.13 $1.85
Average True Range (ATR) 0.53 0.10
MACD -0.14 0.01
Stochastic Oscillator 2.40 32.00

Price Performance

Historical Comparison
BWEN
ENGN

About BWEN Broadwind Inc.

Broadwind Inc is a precision manufacturer of structures, equipment, and components for clean technology and other specialized applications. The company provides technologically high-value products to customers with complex systems and stringent quality standards that operate in the energy, mining, and infrastructure sectors in the United States of America. Its capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treatment, CNG decompression, precision machining, assembly, engineering, and packaging solutions, among others. The company operates in four reportable segments: Heavy Fabrications, which generates the maximum revenue, Gearing, Industrial Solutions, and Corporate.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: